Related Experiment Video
Updated: Nov 22, 2025

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
Published on: August 16, 2017
Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016
Ekaterina Galkina Cleary1, Laura M McNamee2, Skyler de Boer3
1Department of Mathematical Sciences, Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, United States of America.
Abstract:
We compared the financial performance of 319 BIOTECH companies focused on developing therapeutics with IPOs from 1997-2016, to that of paired, non-biotech CONTROL companies with concurrent IPO dates. BIOTECH companies had a distinctly different financial structure with high R&D expense, little revenue, and negative profits (losses), but a similar duration of listing on public markets and frequency of acquisitions. Through 2016, BIOTECH and CONTROL companies had equivalent growth in market cap and shareholder value (>$100 billion), but BIOTECH companies had lower net value creation ($93 billion vs $411 billion). Both cohorts exhibited a high-risk/high reward pattern of return, with the majority losing value, but many achieving growth multiples. While investments in biotechnology are often considered to be distinctively risky, we conclude that value creation by biotech companies after IPO resembles that of non-biotech companies at a similar stage and does not present a disproportionate investment risk.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence Data: Statistical Interpretation
Bioequivalence: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Product Performance: In Vitro–In Vivo Correlation
Bioequivalence studies: Biowaivers

